Upper Bedding As A Prevention Measure In Childhood Asthma: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$198,075.00
Summary
Asthma has recently been identified as a National health Priority (1) by the Australian Government in view of the increasing prevalence of asthma and its great importance as a public health problem. The total health system costs of asthma are estimated to be in excess of $600 million (2). Recently, feather pillows have been shown to have more than five times less house dust mite allergen than other pillows. To date, several population-based studies have shown that children using feather upper be ....Asthma has recently been identified as a National health Priority (1) by the Australian Government in view of the increasing prevalence of asthma and its great importance as a public health problem. The total health system costs of asthma are estimated to be in excess of $600 million (2). Recently, feather pillows have been shown to have more than five times less house dust mite allergen than other pillows. To date, several population-based studies have shown that children using feather upper bedding are also reported by their parents to have less severe wheeze. These findings call into question the National Asthma Council recommendation that people with asthma who are allergic to house dust mite should use synthetic quilts rather than feather or down (3). However, concerns remain that these important findings may only have occurred because unmeasured factors, such as the socioeconomic status or child diet may be closely related to feather bedding use, and in themselves, protective against asthma. Alternatively, parents of a child with asthma symptoms may be more likely to have chosen non-feather bedding. The best way to address these concerns is to conduct a randomised controlled trial to evaluate whether the use of new feather upper bedding is associated with reduced asthma severity among house dust mite-sensitised children with severe asthma. This study is underway and has support in 2001-2002 from the Financial Markets Foundation for Children. The research will address the following NHMRC Primary Health Care project grant thematic research areas: Evidence based primary health care practice; Quality of primary care; and Illness prevention and health promotion as a primary health care strategy. (1) National Health Priority Areas: Asthma. http:--www.health.gov.au-hsdd-nhpq-asthma-index.htm (2) NH and MRC Evidence Based Clinical Practice Research Program Workshop - December 16-17, 1999. (3) National Asthma Campaign Asthma Management Handbook 1998Read moreRead less
Improving Outcomes In Pregnancies Complicated By Asthma: Understanding Mechanisms And Defining Interventions
Funder
National Health and Medical Research Council
Funding Amount
$707,370.00
Summary
Asthma is a common disease to complicate pregnancy and it is important to identify ways of effectively managing the disease to ensure the fetus has the best possible outcome. The current research focusses on this disease and looks at ways of improving management in pregnancy and improving outcomes for the baby.
Evaluation Of The Associations Between Childhood Asthma Hospitalisations, Outdoor Fungal Spores And Environmental Effect Modifiers.
Funder
National Health and Medical Research Council
Funding Amount
$141,558.00
Summary
Asthma is a major cause of childhood hospital admission, impairs quality of life, contributes to high financial burdens on families and health system and can lead to chronic lung problems. Little is known about the combined effects of outdoor fungi, air pollutants and viruses in causing asthma exacerbations. This research aims to investigate the role of outdoor fungi in child asthma hospitalisations and how their role links with respiratory viral infections and changes in air quality.
Prevalence Of Challenge-proven Food Allergy And Predictors Of Severe Adverse Reactions To Food In Early Adolescence: SchoolNuts
Funder
National Health and Medical Research Council
Funding Amount
$1,196,852.00
Summary
Food allergy (FA) has risen to epidemic proportions in recent times and Australia has one of the highest rates in the world. FA is most common in children under 5 years, yet adolescents are at the greatest risk of death from food-related anaphylaxis. We don’t know why this is the case. Our research will describe FA prevalence and will assess the factors placing FA adolescents at high risk of severe allergic reactions. Findings will influence policy for management of FA and anaphylaxis.
Environmental Exposure, Human Behaviour And Respiratory Health For Children With Asthma
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
This research program will examine whether environment and behaviour work together on asthma for Australian children. Calculation on satellite-derived data will establish updated knowledge base for assessing childhood asthma in relation to residential green spaces and local climate. Significance of the research lies in the high prevalence of asthma in Australian children. Findings will help health workers allocate resources for preventing asthma attacks and provide evidence for urban planning.
Exploring The Role Of Respiratory Virus Infections In Childhood Asthma Exacerbations
Funder
National Health and Medical Research Council
Funding Amount
$596,649.00
Summary
The PEAK study will explore the reasons children get worse asthma symptoms when they get colds. These reasons examined include the asthma medications taken (or not taken), allergies and exposure to allergens and the type of virus involved. The study follows the children over the whole school term and uses a new way to sample virus by collecting it in the breath, this is more comfortable than old methods and can be done at home.
Adolescent Assessment Of The Perth Infant Respiratory Cohort
Funder
National Health and Medical Research Council
Funding Amount
$412,327.00
Summary
In spite of extensive research over several years, we still don t know why some people get asthma while others do not or at what age the disease begins. We also don t know why in some people, asthma resolves during the teenage years while in other people the disease persists through adolescence. The Perth respiratory cohort has been studied on repeated occasions (at recruitment prior to birth, 1, 6 and 12 months, 6 and 11 years of age) and is unique in having measured airway responsiveness (AR) ....In spite of extensive research over several years, we still don t know why some people get asthma while others do not or at what age the disease begins. We also don t know why in some people, asthma resolves during the teenage years while in other people the disease persists through adolescence. The Perth respiratory cohort has been studied on repeated occasions (at recruitment prior to birth, 1, 6 and 12 months, 6 and 11 years of age) and is unique in having measured airway responsiveness (AR) soon after birth and at each subsequent assessment. Our previous data have established the importance of an individual s airway status in infancy in determining respiratory health in mid-childhood. Since the last assessment at 11 years, most children in this cohort will have passed through puberty. Lung growth will have been maximal, but there will be differences in the rate of growth between boys and girls. Body size will also have increased during this period and the body mass index may start to exert a major influence on measured respiratory function and the development or persistence of asthma. The aim of this research (assessing the Perth respiratory cohort at 16 years of age) is to look at the effect of gender, puberty and obesity on the previously identified early life risk factors to see how they determine respiratory health in 16 year olds. We expect that airway status in early life will continue to predict respiratory health at 16 years of age and that respiratory health will be modified by gender, puberty and the development of obesity. In addition we expect that genetic variations will show age-specificity in their associations with disease outcomes ie. particular variations will be associated with disease at different ages. This study will answer fundamental questions on airway function and physiology through childhood and adolescence.Read moreRead less
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less